Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Status: Enrolling
Updated:  12/31/1969
Philadelphia FIGHT
2375
mi
from 91732
Philadelphia, PA
Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Status: Enrolling
Updated: 12/31/1969
Philadelphia FIGHT
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)
Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV
Status: Enrolling
Updated:  12/31/1969
Columbia University School for Nursing
2435
mi
from 91732
New York, NY
mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)
Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV
Status: Enrolling
Updated: 12/31/1969
Columbia University School for Nursing
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Mills Clinical Research
13
mi
from 91732
Los Angeles, CA
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Mills Clinical Research
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Ucsd Antiviral Research Center (Avrc)
105
mi
from 91732
San Diego, CA
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Ucsd Antiviral Research Center (Avrc)
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Midway Immunology and Research Center
2271
mi
from 91732
Fort Pierce, FL
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Midway Immunology and Research Center
2271
mi
from 91732
Fort Pierce, FL
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Orlando Immunology Center Recruiting
2184
mi
from 91732
Orlando, FL
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Orlando Immunology Center Recruiting
2184
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Ohio State University Infectious Diseases Research
1960
mi
from 91732
Columbus, OH
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Ohio State University Infectious Diseases Research
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Central Texas Clinical Research
1212
mi
from 91732
Austin, TX
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Central Texas Clinical Research
1212
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated:  12/31/1969
Peter Shalit, M.D.
961
mi
from 91732
Seattle, WA
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status: Enrolling
Updated: 12/31/1969
Peter Shalit, M.D.
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Ucsd, Avrc Crs
103
mi
from 91732
San Diego, CA
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Ucsd, Avrc Crs
103
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS
22
mi
from 91732
Torrance, CA
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS
22
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS
825
mi
from 91732
Aurora, CO
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS
1730
mi
from 91732
Chicago, IL
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital ACTG CRS
2578
mi
from 91732
Boston, MA
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital ACTG CRS
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Washington U CRS
1569
mi
from 91732
Saint Louis, MO
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Washington U CRS
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
MetroHealth CRS
2031
mi
from 91732
Cleveland, OH
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
MetroHealth CRS
2031
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS
1357
mi
from 91732
Houston, TX
Combination Pain Therapy in HIV Neuropathy
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Change the Cycle: An RCT to Prevent Injection Initiation
Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
University of Southern California
11
mi
from 91732
Los Angeles, CA
Change the Cycle: An RCT to Prevent Injection Initiation
Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
University of Southern California
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Change the Cycle: An RCT to Prevent Injection Initiation
Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
RTI International
355
mi
from 91732
San Francisco, CA
Change the Cycle: An RCT to Prevent Injection Initiation
Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
RTI International
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
3BNC117 and 10-1074 in HIV-infected Individuals
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
Status: Enrolling
Updated:  12/31/1969
Rockefeller University
2432
mi
from 91732
New York, NY
3BNC117 and 10-1074 in HIV-infected Individuals
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
Status: Enrolling
Updated: 12/31/1969
Rockefeller University
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
3BNC117 and 10-1074 in HIV-infected Individuals
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
Status: Enrolling
Updated:  12/31/1969
University Hospital of Cologne
mi
from 91732
Cologne,
3BNC117 and 10-1074 in HIV-infected Individuals
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
Status: Enrolling
Updated: 12/31/1969
University Hospital of Cologne
mi
from 91732
Cologne,
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Status: Enrolling
Updated:  12/31/1969
Penn Prevention Crs
2373
mi
from 91732
Philadelphia, PA
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Status: Enrolling
Updated: 12/31/1969
Penn Prevention Crs
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Status: Enrolling
Updated:  12/31/1969
Columbia P&S CRS
2435
mi
from 91732
New York, NY
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Status: Enrolling
Updated: 12/31/1969
Columbia P&S CRS
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Status: Enrolling
Updated:  12/31/1969
New York Blood Center CRS
2434
mi
from 91732
New York, NY
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US
Status: Enrolling
Updated: 12/31/1969
New York Blood Center CRS
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Trauma Intervention for Affect Regulation, AIDS, and Substances
Trauma Intervention for Affect Regulation, AIDS, and Substances
Status: Enrolling
Updated:  12/31/1969
Clinical Research Building
2322
mi
from 91732
Miami, FL
Trauma Intervention for Affect Regulation, AIDS, and Substances
Trauma Intervention for Affect Regulation, AIDS, and Substances
Status: Enrolling
Updated: 12/31/1969
Clinical Research Building
2322
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
343
mi
from 91732
Phoenix, AZ
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1459
mi
from 91732
Little Rock, AR
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1459
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
22
mi
from 91732
Long Beach, CA
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
22
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
22
mi
from 91732
Torrance, CA
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
22
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
819
mi
from 91732
Denver, CO
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
819
mi
from 91732
Denver, CO
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2281
mi
from 91732
Washington,
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2273
mi
from 91732
Fort Pierce, FL
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2273
mi
from 91732
Fort Pierce, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1922
mi
from 91732
Atlanta, GA
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1570
mi
from 91732
Saint Louis, MO
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2400
mi
from 91732
Hillsborough, NJ
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2400
mi
from 91732
Hillsborough, NJ
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2102
mi
from 91732
Columbia, SC
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2102
mi
from 91732
Columbia, SC
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1211
mi
from 91732
Austin, TX
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1211
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1223
mi
from 91732
Dallas, TX
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1357
mi
from 91732
Houston, TX
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
963
mi
from 91732
Seattle, WA
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
963
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
7513
mi
from 91732
Darlinghurst,
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
7513
mi
from 91732
Darlinghurst,
Click here to add this to my saved trials
Non Invasive Oral Cancer Screening Among HIV Infected Individuals
Non-invasive Oral Cancer Screening Among Individuals Who Have HIV Infection
Status: Enrolling
Updated:  12/31/1969
Bering Omega/Houston Area Community Services
1356
mi
from 91732
Houston, TX
Non Invasive Oral Cancer Screening Among HIV Infected Individuals
Non-invasive Oral Cancer Screening Among Individuals Who Have HIV Infection
Status: Enrolling
Updated: 12/31/1969
Bering Omega/Houston Area Community Services
1356
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Sex Hormone Therapy and Mucosal Tissues
Does Sex Hormone Therapy Decrease Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Active Metabolite Formation in Mucosal Tissues?
Status: Enrolling
Updated:  12/31/1969
Clinical and Translational Research Center, UNC Hospitals
1991
mi
from 91732
Chapel Hill, NC
Sex Hormone Therapy and Mucosal Tissues
Does Sex Hormone Therapy Decrease Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Active Metabolite Formation in Mucosal Tissues?
Status: Enrolling
Updated: 12/31/1969
Clinical and Translational Research Center, UNC Hospitals
1991
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Mapping the Human HIV Chronobiome
Mapping the Human HIV Chronobiome
Status: Enrolling
Updated:  12/31/1969
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine
2373
mi
from 91732
Philadelphia, PA
Mapping the Human HIV Chronobiome
Mapping the Human HIV Chronobiome
Status: Enrolling
Updated: 12/31/1969
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2273
mi
from 91732
Fort Pierce, FL
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2273
mi
from 91732
Fort Pierce, FL
Click here to add this to my saved trials